Preclinical studies have further shown that decitabine‐induced CD70 upregulation sensitizes AML LSCs to cusatuzumab, with the combination leading to a marked reduction of functional LSCs in vitro and in vivo. This evidence concerns the gene CD70 and acute myeloid leukemia.